Florida vs Texas Cannabis Laws

Florida is the largest medical-only cannabis market in the United States and one of the most important markets for publicly traded cannabis companies. Amendment 2 legalized medical cannabis in 2016 with 71% voter approval, and the state's medical program has grown to serve over 850,000 active patients — the largest patient registry in the nation. Annual medical cannabis sales exceed $2.5 billion.

The Florida market operates under a vertically integrated license model known as MMTC (Medical Marijuana Treatment Center) licenses. Each licensee must cultivate, process, and dispense its own cannabis products, creating high barriers to entry but also protecting established operators from new competition. The state has issued a limited number of licenses, making each one extremely valuable. A 2024 ballot measure to legalize recreational cannabis received 57% voter support but fell short of Florida's 60% supermajority threshold.

Florida is a critical market for nearly every major MSO. Trulieve, which is headquartered in the state, operates the largest dispensary network with over 130 locations. Curaleaf, Green Thumb Industries, Cresco Labs, Verano, TerrAscend, and Ayr Wellness also maintain significant Florida operations. The state's large population of 22 million, strong tourism industry, and affluent retiree demographic make it one of the most commercially attractive cannabis markets regardless of its medical-only status.

Texas has one of the most restrictive medical cannabis programs in the country. The Texas Compassionate Use Act, signed in 2015, created the Compassionate Use Program (CUP), initially limited to patients with intractable epilepsy and restricted to low-THC cannabis products. HB 1535, passed in 2021, expanded the program to include additional qualifying conditions such as cancer, PTSD, and certain neurodegenerative diseases, and raised the THC cap from 0.5% to 1%. Despite these expansions, the program remains far more limited than standard medical cannabis programs in other states.

The Texas market structure is extraordinarily restrictive. Only 3 vertically integrated dispensing organizations are licensed to operate statewide, serving a population of approximately 30 million people. This creates significant access challenges for patients, as the limited number of dispensary locations cannot adequately serve the state's vast geography. Products are limited to low-THC cannabis preparations, and the 1% THC cap means patients cannot access the full-potency products available in most medical states.

Despite being the second most populous state, Texas generates modest cannabis revenue estimated at roughly $50 million annually from its CUP program. The extremely limited license structure, low THC cap, and restricted qualifying conditions severely constrain the market. No major MSOs currently operate in Texas, as the 3 existing licenses are held by local operators. If Texas were to significantly expand its medical program or legalize recreational cannabis, it would instantly become one of the largest cannabis markets in the world. Market analysts estimate a fully legalized Texas market could generate $3-5 billion in annual sales, making it a closely watched state for potential reform.